BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15779438)

  • 1. [Treatment for coronary artery disease patients with impaired glucose tolerance].
    Kume A; Miyazaki T; Daida H
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():543-7. PubMed ID: 15779438
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pathophysiological conditions progressing from impaired glucose tolerance: coronary artery disease (ischemic heart disease)].
    Tomono S; Uchiyama T; Ohyama Y
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():255-9. PubMed ID: 15779382
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pathophysiological conditions progressing from impaired glucose tolerance: atherosclerosis].
    Yokote K; Saito Y
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():250-4. PubMed ID: 15779381
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
    Sakamoto N; Tajima N
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
    [No Abstract]   [Full Text] [Related]  

  • 5. [Characteristic of metformin for treatment of impaired glucose tolerance].
    Ishida W; Satoh J
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():433-7. PubMed ID: 15779418
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical Inquiries: How can we keep impaired glucose tolerance and impaired fasting glucose from progressing to diabetes?
    Swanson A; Watrin K; Wilder L
    J Fam Pract; 2010 Sep; 59(9):532-3. PubMed ID: 20824232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
    Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
    Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of type 2 diabetes in the prediabetic population.
    Maji D; Roy RU; Das S
    J Indian Med Assoc; 2005 Nov; 103(11):609-11. PubMed ID: 16570766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevention by life style intervention and medication. To run away from type 2 diabetes].
    Wepner U
    MMW Fortschr Med; 2004 Apr; 146(14):16. PubMed ID: 15344745
    [No Abstract]   [Full Text] [Related]  

  • 10. [Diabetes prevention program (metformin)].
    Kusaka I; Nagasaka S
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():471-7. PubMed ID: 15779424
    [No Abstract]   [Full Text] [Related]  

  • 11. [Coronary artery disease in patients with diabetes mellitus and its treatment].
    Teramoto T
    Nihon Naika Gakkai Zasshi; 2002 Mar; 91 Suppl():94-9. PubMed ID: 11989270
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U
    Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impaired glucose tolerance in patients with ischemic heart diseases].
    Yasuda S; Miyazaki S
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():300-2. PubMed ID: 15779392
    [No Abstract]   [Full Text] [Related]  

  • 15. [Childhood obesity increases the risk of coronary artery disease].
    Nuutinen O; Nuutinen M
    Duodecim; 2001; 117(13):1356-62. PubMed ID: 12184126
    [No Abstract]   [Full Text] [Related]  

  • 16. Association of diet alone, insulin, sulfonylureas, metformin, and thiazolidinediones with the severity of coronary artery disease in patients with diabetes mellitus.
    Ravipati G; Aronow WS; Ahn C; Sujata K; Saulle LN; Channamsetty V; Weiss MB
    Am J Ther; 2006; 13(5):400-3. PubMed ID: 16988534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
    Caro JJ; Getsios D; Caro I; Klittich WS; O'Brien JA
    Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.
    Omer Z; Cetinkalp S; Akyildiz M; Yilmaz F; Batur Y; Yilmaz C; Akarca U
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):18-23. PubMed ID: 19667999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The impaired glucose tolerance in the pathogenesis of dyslipidemia].
    Ikoue I; Takahashi K; Katayama S
    Nihon Rinsho; 1996 Oct; 54(10):2672-8. PubMed ID: 8914426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of hypertensive patients with impaired glucose tolerance (IGT)].
    Yoshida D; Higashiura K; Shimamoto K
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():533-7. PubMed ID: 15779436
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.